SAB Biotherapeutics’ (SABS) “Buy” Rating Reaffirmed at Chardan Capital

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “buy” rating reissued by Chardan Capital in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $25.00 target price on the stock.

Several other equities analysts also recently weighed in on SABS. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of SAB Biotherapeutics in a research report on Wednesday. Craig Hallum started coverage on shares of SAB Biotherapeutics in a report on Wednesday, October 9th. They set a “buy” rating and a $11.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $12.40.

SAB Biotherapeutics Stock Performance

Shares of SABS traded up $0.21 during trading hours on Wednesday, reaching $2.28. 578,489 shares of the company traded hands, compared to its average volume of 179,638. The company has a quick ratio of 3.69, a current ratio of 3.69 and a debt-to-equity ratio of 0.09. The stock has a fifty day simple moving average of $3.63 and a 200 day simple moving average of $3.13. SAB Biotherapeutics has a fifty-two week low of $2.01 and a fifty-two week high of $6.30.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. Equities research analysts predict that SAB Biotherapeutics will post -3.69 EPS for the current year.

Institutional Investors Weigh In On SAB Biotherapeutics

A hedge fund recently raised its stake in SAB Biotherapeutics stock. HB Wealth Management LLC lifted its stake in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) by 118.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 237,400 shares of the company’s stock after buying an additional 128,800 shares during the quarter. HB Wealth Management LLC owned approximately 2.57% of SAB Biotherapeutics worth $982,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.